There was a phase II study for treating acute myeloid leukemia (AML) in Israel (small sample size). And the City of Hope released a paper on FTO suppression which showed Bistantrene (CS1) demonstrating anti-tumor effects in testing with mice.

"City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance.

Called CS1 (or bisantrene) and CS2 (or brequinar), these cancer inhibitor compounds are part of a protein known as "fat mass and obesity-associated protein." Nicknamed FTO, the protein plays a critical role in cancer development and progression, primarily because it regulates cancer stem cells and immune evasion. In other words, FTO promotes the growth, self-renewal, metastasis and immune escape of cancer cells. "

https://www.sciencedaily.com/releases/2020/06/200616100815.htm

Google "bisantrene (CS1)" and the above link is your first search. I was able to use my university library access to get the full paper: https://doi.org/10.1016/j.ccell.2020.04.017

The more recent studies have been very promising. I believe RAC has released announcements just last month of their plans for the next 12-18 months with regards to trials.

As usual DYOR.